Biochemical freedom from failure
WebMulticenter Analysis of Effect of High Biologic Effective Dose on Biochemical Failure and Survival Outcomes in Patients With Gleason Score 7–10 Prostate Cancer Treated With Permanent Prostate Brachytherapy Nelson N. Stone, Louis Potters, Brian J. Davis, Jay P. Ciezki, ... Richard G. Stock WebThe 7-year biochemical freedom from failure for low-, intermediate-, and selected high-risk prostate cancers were 98%, 93%, and 81%, respectively (p < 0.001). Multivariate …
Biochemical freedom from failure
Did you know?
WebMar 14, 2016 · Dose-escalated EBRT has been shown in several studies to improve biochemical freedom from failure in patients with intermediate- to high-risk prostate cancer. However, the impact of adding AST to EBRT on cause-specific and overall survival has been much more consistent and pronounced. WebMar 25, 2024 · The Seattle Isotope trial randomized low-risk prostate cancer pts to I-125 vs. Pd-103 and found no difference in 3-yr biochemical freedom from failure (89% vs. 91%, p = 0.76) and no ... Younger pts appear more likely to have a bounce. Bounces of >2 ng/mL (i.e., biochemical failure by Phoenix definition) may occur in 15% of pts. However, PSA ...
WebJan 1, 2008 · Background: The American Society for Therapeutic Radiology and Oncology (ASTRO) definition of biochemical failure (BF) incorporates backdating, resulting in an artificial flattening of Kaplan-Meier curves and overly favorable estimates when follow-up is short. The nadir + 2 ng/mL (Nadir + 2; Phoenix) definition reduces these artifacts. The … WebBiochemical Failure After Treatment Posted by Stephen J. Freedland, MD Apr 2015 Dr. Stephen J. Freedland spoke at the 25th International Prostate Cancer Update on Friday, January 23, 2015 on “Biochemical Failure …
WebBIOCHEMICAL ANALYSIS. Full Record Related Research Authors: D'Eustachio, A J Publication Date: Mon Jan 01 00:00:00 EST 1968 Research Org.: E. I. du Pont de Nemours and Co., Inc., Wilmington, Del. Sponsoring Org.: USDOE OSTI Identifier: 4537097 NSA Number: NSA-22-025271 Resource Type: Journal Article Journal Name: WebFeb 1, 2011 · In 648 men at high risk the biochemical freedom from failure rate was 67% and significant predictors were hormonal therapy, Gleason score and biologically effective dose (p = 0.036, <0.001 and...
WebPurpose Assess the importance of overall time (OT) and dose for biochemical failure (BF) after external-beam radiotherapy of prostate cancer in a retrospective analysis of a nine-institution database with 4839 patients. Patients and methods Relevant baseline factors (T stage, Gleason score, initial PSA) were available for 4338 men. Cox models were used …
WebNov 1, 2000 · Freedom from biochemical failure was defined as a serum PSA < or = 0.5 ng/mL at last follow-up. The biochemical control rate at 3 years for all 499 patients was 86%, with 348 patients followed ... phoebus tacticalWebFeb 1, 2009 · Patients were stratified on the basis of age: {<=}60 (n = 378) and >60 years (n = 1,287). Biochemical failure was defined as a prostate-specific antigen (PSA) nadir plus 2 ng/mL. Univariate and multivariate analyses were used to determine the association of variables with freedom from biochemical failure (FFbF). phoebus st idesbaldphoebus symboleWebBiochemical Freedom from Failure 13 Harms zGenitourinary zIncontinence only reported separately in brachytherapy studies (n=15) zPooled rates similar regardless of whether RTOG grading used (1.6% vs. 1.8% respectively) zAcute urinary retention reported in 8 brachytherapy studies: ttc notification 2021WebJun 30, 2015 · The primary endpoint was 24 month biochemical freedom from failure (the “Phoenix” definition). Subjects underwent biopsy for cause (rising PSA) or at the end of study (24 months). Adverse events were assessed at each postoperative visit and reported as mild, moderate or severe and related to the device or procedure at 24 months. ... ttcnshWebBiochemical freedom from failure (BFFF) was computed by the Phoenix definition, freedom from metastasis (FFM) in men with BF by absence of a positive bone or CT scan and cause-specific survival (CSS) by freedom from death in men with clinical recurrence. Association of risk features to GS 9-10 were compared by chi-square and linear … phoebus tassopoulosWebWith longer follow-up, Tendulkar and colleagues 83 demonstrated an improvement in metastasis-free survival in addition to biochemical recurrence. The freedom from biochemical failure decreased from 71% for those with a presalvage PSA of 0.01 to 0.2 … Peyman Hadji, in Marcus and Feldman's Osteoporosis (Fifth Edition), 2024. … With a median follow-up of 7.8 years, 10-year freedom from biochemical failure … phoebus tactical flashlight